GlassScriptPhysician profile
Lynn C Mclaughlin
NPI 1073573184
$3,885.83
in general payments reported to CMS, 2019-2025
20 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $391 · 2023: $476 · 2024: $1,383 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.18 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.88 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $456.60 | 2021-2025 | |
| Lilly USA, LLC | $413.55 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $395.11 | 2022-2025 | Sotyktu |
| Amgen INC. | $361.77 | 2021-2025 | Otezla, Otezla, Enbrel |
| Regeneron Healthcare Solutions, INC. | $254.12 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $225.37 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $192.30 | 2022-2025 | Tremfya |
| Ucb, INC. | $164.94 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $161.60 | 2021-2025 | |
| Galderma Laboratories, L.P. | $155.64 | 2024-2025 | Nemluvio |
| Pfizer INC. | $134.64 | 2021-2025 | |
| Leo Pharma INC. | $131.21 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $90.53 | 2021-2025 | |
| Botanix Sb INC | $77.07 | 2025 | Sofdra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $69.34 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.76 | 2022-2024 | Jublia, Arazlo, Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.62 | 2023 | Cyltezo, Spevigo |
| Lnhc, INC | $14.47 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $5.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.